2023
Oral Vancomycin Induced and Maintained Clinical and Endoscopic Remission in Ulcerative Colitis and Primary Sclerosing Cholangitis Post-liver Transplantation
Almomen H, Al-Bawardy B. Oral Vancomycin Induced and Maintained Clinical and Endoscopic Remission in Ulcerative Colitis and Primary Sclerosing Cholangitis Post-liver Transplantation. Inflammatory Bowel Diseases 2023, 29: 837-838. PMID: 36888548, DOI: 10.1093/ibd/izad040.Peer-Reviewed Original Research
2022
Effect of obesity on vedolizumab response in inflammatory bowel disease
Levine LJ, Gaidos JKJ, Proctor DD, Viana AV, Al-Bawardy B. Effect of obesity on vedolizumab response in inflammatory bowel disease. Annals Of Gastroenterology 2022, 35: 275-280. PMID: 35599926, PMCID: PMC9062841, DOI: 10.20524/aog.2022.0699.Peer-Reviewed Original ResearchBody mass indexInflammatory bowel diseaseSteroid-free clinical remissionNon-obese groupC-reactive proteinObese groupCRP normalizationEndoscopic remissionIBD patientsBowel diseaseDose escalationNormal serum C-reactive proteinMedian body mass indexSerum C-reactive proteinHigher body mass indexEndoscopic remission ratesEffect of obesityVedolizumab discontinuationVedolizumab levelsClinical remissionMedian followRemission rateSecondary outcomesMedian agePrimary outcome